
|Videos|April 18, 2019
HR+ Metastatic Breast Cancer
HR+ Metastatic Breast Cancer
Advertisement
Case: A 58-Year-Old Woman With Metastatic ER+ Ductal Carcinoma
- 58-year-old woman with estrogen-receptor-positive (ER+), progesterone-receptor-negative (PR-), HER2-negative (HER2-) invasive ductal carcinoma (IDC) of L breast; she completed adjuvant anastrozole for 5 years
- Now, 13 months later, she presents with 4 small (<1.0 cm) asymptomatic lesions in the left lung and mediastinal and hilar lymphadenopathy.
- Mediastinoscopy was performed and confirmed ER+ PR- Her2- carcinoma
- ECOG PS: 0
- The patient was started on abemaciclib + fulvestrant
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































